Loading...
•
Dec 28, 2025
Johnson & Johnson Q4 2025 Earnings Report
Johnson & Johnson reported strong fourth-quarter results, driven by robust growth in oncology and neuroscience segments.
Key Takeaways
Johnson & Johnson delivered solid Q4 results with $24.6B in revenue and $5.1B in net income. EPS reached $2.10 ($2.46 adj.), supported by strong performance in its Innovative Medicine and MedTech businesses.
EPS came in at $2.10 and adjusted EPS at $2.46, driven by strong product performance.
Q4 revenue rose to $24.6B, led by growth in both Innovative Medicine and MedTech segments.
Net income rose to $5.1B, boosted by reduced R&D expenses and operational efficiency.
Company submitted the OTTAVA Robotic Surgical System and completed the Halda Therapeutics acquisition.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
For FY2026, Johnson & Johnson expects reported sales of $100.5B and adjusted EPS of $11.53 at the midpoint.
Positive Outlook
- Estimated reported sales midpoint of $100.5B, up from $94.2B
- Adjusted EPS forecast midpoint of $11.53
- Adjusted operational EPS growth guided at 5.5%
- Strong product pipeline across multiple therapeutic areas
- Continued momentum from recent approvals and innovations
Challenges Ahead
- No GAAP guidance provided due to legal and acquisition uncertainties
- Pressure from currency translation continues
- Ongoing restructuring in MedTech segments may incur short-term costs
- Potential headwinds from STELARA patent expiration
- Macroeconomic uncertainties may affect international operations
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...